---
figid: PMC6333970__crt-2018-031f5
figtitle: Blockade interlukin (IL)-11/IL-11R signal relieves chemotherapy drug resistance
  in gastric cancer
organisms:
- Homo sapiens
- Mus musculus
- Bos taurus
organisms_ner:
- Bos taurus
- Homo sapiens
- Mus musculus
- Arabidopsis thaliana
pmcid: PMC6333970
filename: crt-2018-031f5.jpg
figlink: /pmc/articles/PMC6333970/figure/f5-crt-2018-031/
number: F5
caption: Blockade interlukin (IL)-11/IL-11R signal relieves chemotherapy drug resistance
  in gastric cancer. (A) The mean tumor volume of NOD-SCID mice bearing SGC7901 cells
  implants in phosphate buffered saline (PBS), doxorubicin, ruxolitinib, or doxorubicin
  combing ruxolitinib (left); the long-term survival of tumor bearing mice treated
  with PBS, doxorubicin, ruxolitinib, or doxorubicin combing ruxolitinib (right).
  Eto, etoposide; Dox, doxorubicin. (B) The mean tumor volume of NOD-SCID mice bearing
  SGC7901 cells implants in PBS, etoposide, ruxolitinib, or etoposide combing ruxolitinib
  (left); the long-term survival of tumor bearing mice treated with PBS, etoposide,
  ruxolitinib, or etoposide combing ruxolitinib (right). (C) The mean tumor volume
  of NOD-SCID mice bearing SGC7901 cells implants in PBS, DDP, ruxolitinib, or DDP
  combing ruxolitinib (left); the long-term survival of tumor bearing mice treated
  with PBS, DDP, ruxolitinib, or DDP combing ruxolitinib (right). (D) The mean tumor
  volume of NOD-SCID mice bearing SGC7901 cells injected with rhIL-11 and then treated
  with PBS, doxorubicin, ruxolitinib, or doxorubicin combing ruxolitinib (left); the
  long-term survival of NOD-SCID mice bearing SGC7901 cells injected with rhIL-11
  (2.5 μg/kg) and then treated with PBS, doxorubicin, ruxolitinib, or doxorubicin
  combing ruxolitinib (right). (E) The mean tumor volume of NOD-SCID mice bearing
  SGC7901 cells injected with rhIL-11 (2.5 μg/kg) and then treated with PBS, etoposide,
  ruxolitinib, or etoposide combing ruxolitinib (left); the long-term survival of
  NOD-SCID mice bearing SGC7901 cells injected with rhIL-11 and then treated with
  PBS, etoposide, ruxolitinib, or etoposide combing ruxolitinib (right). (F) The mean
  tumor volume of NOD-SCID mice bearing SGC7901 cells injected with rhIL-11 (2.5 μg/kg)
  and then treated with PBS, DDP, ruxolitinib, or DDP combing ruxolitinib (left);
  the long-term survival of NOD-SCID mice bearing SGC7901 cells injected with rhIL-11
  and then treated with PBS, DDP, ruxolitinib, or DDP combing ruxolitinib (right).
  (G) The schematic diagram of drug resistance development induced by IL-11 in gastric
  cancer cells. The data was presented as the mean±standard error of mean from three
  independent experiments. **p < 0.01, ***p < 0.001.
papertitle: Cancer-Associated Fibroblasts Promote the Chemo-resistance in Gastric
  Cancer through Secreting IL-11 Targeting JAK/STAT3/Bcl2 Pathway.
reftext: Jun Ma, et al. Cancer Res Treat. 2019 Jan;51(1):194-210.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.6274778
figid_alias: PMC6333970__F5
figtype: Figure
redirect_from: /figures/PMC6333970__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6333970__crt-2018-031f5.html
  '@type': Dataset
  description: Blockade interlukin (IL)-11/IL-11R signal relieves chemotherapy drug
    resistance in gastric cancer. (A) The mean tumor volume of NOD-SCID mice bearing
    SGC7901 cells implants in phosphate buffered saline (PBS), doxorubicin, ruxolitinib,
    or doxorubicin combing ruxolitinib (left); the long-term survival of tumor bearing
    mice treated with PBS, doxorubicin, ruxolitinib, or doxorubicin combing ruxolitinib
    (right). Eto, etoposide; Dox, doxorubicin. (B) The mean tumor volume of NOD-SCID
    mice bearing SGC7901 cells implants in PBS, etoposide, ruxolitinib, or etoposide
    combing ruxolitinib (left); the long-term survival of tumor bearing mice treated
    with PBS, etoposide, ruxolitinib, or etoposide combing ruxolitinib (right). (C)
    The mean tumor volume of NOD-SCID mice bearing SGC7901 cells implants in PBS,
    DDP, ruxolitinib, or DDP combing ruxolitinib (left); the long-term survival of
    tumor bearing mice treated with PBS, DDP, ruxolitinib, or DDP combing ruxolitinib
    (right). (D) The mean tumor volume of NOD-SCID mice bearing SGC7901 cells injected
    with rhIL-11 and then treated with PBS, doxorubicin, ruxolitinib, or doxorubicin
    combing ruxolitinib (left); the long-term survival of NOD-SCID mice bearing SGC7901
    cells injected with rhIL-11 (2.5 μg/kg) and then treated with PBS, doxorubicin,
    ruxolitinib, or doxorubicin combing ruxolitinib (right). (E) The mean tumor volume
    of NOD-SCID mice bearing SGC7901 cells injected with rhIL-11 (2.5 μg/kg) and then
    treated with PBS, etoposide, ruxolitinib, or etoposide combing ruxolitinib (left);
    the long-term survival of NOD-SCID mice bearing SGC7901 cells injected with rhIL-11
    and then treated with PBS, etoposide, ruxolitinib, or etoposide combing ruxolitinib
    (right). (F) The mean tumor volume of NOD-SCID mice bearing SGC7901 cells injected
    with rhIL-11 (2.5 μg/kg) and then treated with PBS, DDP, ruxolitinib, or DDP combing
    ruxolitinib (left); the long-term survival of NOD-SCID mice bearing SGC7901 cells
    injected with rhIL-11 and then treated with PBS, DDP, ruxolitinib, or DDP combing
    ruxolitinib (right). (G) The schematic diagram of drug resistance development
    induced by IL-11 in gastric cancer cells. The data was presented as the mean±standard
    error of mean from three independent experiments. **p < 0.01, ***p < 0.001.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IL11
  - STAT3
  - BCL2
  - CM
  - RUNX1T1
  - TIMM8A
  - TBX1
  - IL6ST
  - NM
  - LRPPRC
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - PBC2
  - Runx1t1
  - Il11
  - Il11ra1
  - Il6st
  - Lrpprc
  - Stat3
  - Bcl2
  - Cm
  - PBC1
  - CM3
  - Dox
  - Ruxolitinib
  - ruxolitinib
  - Dox-ruxolitinib
  - Eto
  - DDP
  - DDPeruxolitinib
  - Buxolibnib
---
